TIL the end: Tracking T cell clonotype dynamics during adoptive cell therapy

IF 25.5 1区医学 Q1 IMMUNOLOGY

Immunity Pub Date : 2024-10-08 DOI:10.1016/j.immuni.2024.09.012

Anthony C. Buzzai, Thomas Tüting

引用次数: 0

Abstract

Understanding the factors that lead to the therapeutic success of adoptive cell therapies using tumor-infiltrating lymphocytes (TIL-ACT) will improve current treatment protocols. In this issue of Immunity, Chiffelle et al. comprehensively compare the dynamics of CD8⁺ T cell clonotypes during the course of ACT between responding and non-responding patients.

查看原文本刊更多论文

TIL 终结：追踪采用细胞疗法期间 T 细胞克隆型的动态变化

了解导致使用肿瘤浸润淋巴细胞（TIL-ACT）的采纳细胞疗法取得治疗成功的因素将改善目前的治疗方案。在本期《免疫》（Immunity）杂志上，Chiffelle 等人全面比较了有应答和无应答患者在采用 ACT 治疗过程中 CD8+ T 细胞克隆型的动态变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunity 医学-免疫学

CiteScore

49.40

自引率

2.20%

发文量

205

审稿时长

6 months

期刊介绍： Immunity is a publication that focuses on publishing significant advancements in research related to immunology. We encourage the submission of studies that offer groundbreaking immunological discoveries, whether at the molecular, cellular, or whole organism level. Topics of interest encompass a wide range, such as cancer, infectious diseases, neuroimmunology, autoimmune diseases, allergies, mucosal immunity, metabolic diseases, and homeostasis.